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Objectives. To study the development of dizziness, caloric function and postural 47 
sway during long-term observation of untreated vestibular schwannoma patients. 48 
 49 
Study Design: Retrospective review of a prospectively maintained longitudinal cohort. 50 
 51 
Setting: Tertiary referral hospital 52 
 53 
Subjects and Methods. Vestibular schwannoma patients undergoing wait-and-scan 54 
management were included. Baseline data and follow-up with MRI, posturography 55 
and bithermal caloric tests. Dizziness questionnaire. 56 
The study included patients who did not require treatment during a minimum 57 
radiologic follow-up of 1 year. Main outcomes: prevalence of moderate to severe 58 
dizziness, canal paresis and postural instability at baseline and follow-up compared 59 
using McNemar’s test. 60 
 61 
Results. Out of 433 consecutive vestibular schwannoma patients, 114 patients did 62 
not require treatment during follow-up and were included. Median radiologic follow-up 63 
was 10.2 years (IQR 4.5 years). Age ranged from 31 to 78 years (mean 59 years; SD 64 
10 years, 62 % women). 65 
Median tumor volume at baseline was 139 mm3 (IQR  314 mm3). This did not change 66 
during follow-up (P=0.446). 67 
Moderate to severe dizziness was present in 27% at baseline and in 19% at follow-68 
up (P=0.077). Postural unsteadiness was present in 17% at baseline and 21% at 69 
 4 
follow-up (P=0.424). Canal paresis was present in 51% at baseline and 56 % at 70 
follow-up (P=0.664). 71 
 72 
Conclusions. There was no significant change in the prevalence of dizziness, 73 
postural sway or canal paresis during conservative management of vestibular 74 
schwannoma while tumor volume remained unchanged. This indicates a favorable 75 
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 96 
Introduction 97 
Conservative management of vestibular schwannomas with regular magnetic 98 
resonance imaging (MRI) has become a common management strategy in recent 99 
years.  Along with the increased availability of MRI, this “wait-and-scan” policy has 100 
become feasible due to the fact that about 50 % of small to medium sized tumors do 101 
not grow when observed for five years.1 Other management options are mainly 102 
gamma knife radiosurgery (GKR) or microsurgical removal of the tumor. Since 103 
vestibular schwannoma is rarely fatal today, the choice between these management 104 
modalities is increasingly aimed at preserving the quality of life of the patient.  105 
The most common symptoms in untreated vestibular schwannoma patients are 106 
unilateral hearing loss (94-97%), tinnitus (73-83%), unsteadiness (33,5%-63%) and 107 
vertigo (20-49%).2-9 We were the first to demonstrate that vertigo is the strongest 108 
negative predictor of quality of life in patients with vestibular schwannomas. Quality 109 
of life is also affected by unsteadiness.10 These observations were confirmed by 110 
others.3,11-13  111 
Andersen et al14 found that 9% of newly diagnosed vestibular schwannoma patients 112 
reported severe dizziness. We do not fully understand why some patients become 113 
dizzy while others do not, but tumor growth, fluctuations in vestibular function and 114 
comorbidities are likely explanations for the vestibular symptoms in a majority of 115 
cases. 116 
 6 
Usually, vestibular compensation will lead to relief from severe dizziness in most 117 
patients,15 despite damage to the vestibular nerve. Tumor growth is believed to 118 
disturb the vestibular compensation. 119 
Given the impact of vestibular symptoms on quality of life, it is necessary to know the 120 
progression of vestibular function and symptoms if the tumor is left untreated. With 121 
regards to subjective vestibular symptoms there is limited long-term data.12,16-18 No 122 
previous study has to our knowledge reported the long-term development of postural 123 
control during conservative management. 124 
The aim of this study was to investigate the long-term consequences of conservative 125 
vestibular schwannoma management on dizziness, postural instability and caloric 126 
function. 127 
 128 
Materials and Methods 129 
 130 
Patients, Design, Treatment Algorithm and Ethics 131 
This is a retrospective study of a subset of 433 patients newly diagnosed with 132 
sporadic unilateral vestibular schwannoma who were included into a prospectively 133 
maintained database. The 433 patients were included between September 2001 and 134 
March 2010 and followed up at regular intervals (6 months, 1, 2, 5 and 10 years). 135 
Data on management, tumor size, clinical symptoms, hearing and vestibular function 136 
were recorded.10 Our management algorithm and methods for estimating tumor 137 
volumes from MRI scans have been published earlier.19 138 
The patients were elected for conservative management, GKR or microsurgery 139 
according to the following algorithm based on tumor size and growth: Conservative 140 
management (wait-and-scan) was chosen if the tumor was less than 20 mm. GKR 141 
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was chosen for tumors of 20-25 mm, or smaller tumors if there was documented 142 
growth on serial MRI. Microsurgery was the treatment of choice for tumors larger 143 
than 25 mm. 144 
For the present study, we identified and included patients who by August 2018 still 145 
underwent conservative management and had both MRI and either caloric tests or 146 
clinical data at two time points over a time interval of at least one year.  147 
The database and its use for scientific studies were approved by the Norwegian 148 
National Data Inspectorate (NSD 13199) and all patients gave their written informed 149 
consent at inclusion. 150 
 151 
Data collection for the present study 152 
For the present study, we used data on MRI, posturography and bithermal caloric 153 
tests. A questionnaire was filled in including visual analog scale (VAS) scores for 154 
vertigo symptoms, time course and characteristics of dizziness.  155 
Static posturography was carried out using a force platform (Cosmogamma, Bologna, 156 
Italy) containing three pressure transducers. The movement of the center of pressure 157 
was measured while the patients were instructed to stand still and maintain their 158 
balance for 1 minute with eyes open and same procedure with eyes shut. For 159 
statistical analysis, the path length in millimeters with eyes closed was used. For 160 
patients undergoing static posturography at baseline, this method was also used at 161 
follow-up.  162 
Since 2006, postural balance for new patients was measured using dynamic 163 
posturography (EquiTest, NeuroCom, USA) and the Sensory Organization Test 164 
(SOT) protocol. This method involved measuring postural sway under six different 165 
sensory conditions where a combination of movement of platform and the visual 166 
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surroundings were used to challenge the vestibular component of the balance. The 167 
composite score was calculated and used for measuring postural sway. These 168 
procedures are described in a previous study.14 169 
For static posturography, postural sway was defined as the path length in millimeters 170 
with eyes closed. The composite score was used for dynamic posturography. 171 
 172 
Caloric Testing  173 
Slow phase nystagmus velocities were measured by videonystagmography 174 
(Hortmann, Germany) after 30 seconds of irrigation with cold (30-C) and hot (44-C) 175 
water into the external auditory canal. Canal paresis was defined as unilateral 176 
weakness greater than 25% calculated using Jongkees’ formula.20  177 
 178 
Dizziness Symptoms  179 
To quantify dizziness, the patients were asked to answer the question 180 
 “How troublesome is your dizziness usually?” on a 100-mm visual analog scale 181 
(VAS). To make interpretation of the VAS scores more intuitive, we used a grading 182 
system and cut points developed for pain.21 A VAS score 0 to 4 mm was ranged as 183 
‘‘no dizziness,’’ a score of 5 to 44 mm was ranged as ‘‘mild dizziness,’’ a score of 45 184 
to 74 mm was ranged as ‘‘moderate dizziness,’’ and a score of 75 to 100 mm was 185 
ranged as ‘‘severe dizziness’’. 186 
The patients were also asked about the time course of their dizziness (attacks, 187 
periods, constant or no dizziness) and characteristics of dizziness (spinning, rocking, 188 
walking on pillows and other) during the last three months.  189 
 190 
Statistical Analysis 191 
 9 
STATA software (StataCorp, USA) was used for statistical analysis. The dependent 192 
variables were moderate to severe dizziness defined as VAS> 44, canal paresis 193 
greater than 25% and unsteadiness on either of the two posturography platforms. 194 
Normative values between age groups given by Neurocom International22 were used 195 
to define cut points for unsteadiness on the dynamic platform. In static posturography 196 
unsteadiness was defined as path length more than 1600 mm when performed with 197 
eyes closed.23  198 
Data at baseline were compared with data from the last clinical control. McNemar’s 199 
test for paired data (chi square and exact P-values) and paired t-tests were used. P-200 
values less than 0.05 were considered significant. 201 
Results 202 
Out of 433 patients screened at baseline, 223 were selected for wait-and-scan 203 
management. Of these, 114 remained untreated by august 2018 and were included 204 
in the study (Figure 1). Mean age was 59 years (range 31-78 years; SD 10 years) 205 
and 62 % of the patients were female. The median radiologic follow-up was 10.2 206 
years (IQR 4.5 years). Figure 2 shows proportions of patients with dizziness, 207 
unsteadiness and canal paresis from baseline to follow-up. Table 1 shows changes 208 




The distribution of VAS-score at baseline is shown in Figure 3. 213 
Moderate to severe dizziness at baseline were reported by 27% (N=27), and 19% 214 
(N=19) at follow-up. There was no significant change in proportion with dizziness  215 
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from baseline until last follow-up. Median follow-up time for the VAS scores was 3.1 216 
years (IQR 3.1 years). 217 
 218 
Posturography 219 
Static posturography was used for 64 of the patients and dynamic posturography for 220 
40 patients. 17 % (N=18) of the patients were unsteady at baseline and 21 % (N=22) 221 
at last follow-up. There was no significant change in proportion with unsteadiness 222 
from baseline until last follow-up, also when analyzing the static and dynamic 223 
posturography platforms separately. Median follow-up time was 9.1 years (IQR 6.6 224 
years). 225 
 226 
Caloric Testing  227 
Caloric testing was included into the testing protocol from June 2003. 51 % (N=37) of 228 
the patients had canal paresis at baseline, and 56 % (N=40) on the last clinical 229 
control. There was no significant change in the proportion of patients with canal 230 
paresis from baseline until last follow-up. Median follow-up time was 9.1 years (IQR 231 
6.3 years).  232 
 233 
Tumor Volume 234 
114 patients had radiologic follow-up with at least 2 MRI scans with measurements of 235 
tumor volume. Median tumor volume at baseline was 139 mm3 (IQR 314 mm3) and at 236 
last follow-up 139 mm3 (IQR 288mm3). Median follow-up time was 10.2 years (IQR 237 
4.5 years). Mean tumor volume did not change significantly during follow-up, P=0.446 238 
(paired t-test). 239 
 240 
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The time course and characteristics of dizziness are shown in Table 2 and Table 3. 241 
Only 7 percent reported constant dizziness at baseline, and 9 percent after a median 242 
follow-up of 3.5 years.  243 
       
Discussion   244 
 245 
This study found no significant changes in dizziness symptoms, postural balance or 246 
caloric response during long-term conservative management of vestibular 247 
schwannoma. 248 
To our knowledge, this is the first study to investigate long-term development of 249 
objective balance and caloric function in untreated vestibular schwannoma patients.  250 
 251 
The findings indicate a good prognosis in this patient group. In a normal population 252 
proportion of subjects experiencing dizziness and imbalance tends to increase over 253 
time due both to ageing and to age-related diseases. 254 
Du Pasquier et al estimated the postural stability impairment due to aging24 and 255 
Saman measured postural stability in untreated vestibular schwannoma patients 256 
using the functional gait assessment (FGA) scores and found a correlation between 257 
age over 60 years and decreased postural stability.25 258 
 259 
Breivik did not find a significant change in VAS score from baseline to last follow-up, 260 
but a significant decrease in number of patients with vertigo.16 261 
Godefroy et al17 observed 41 vestibular schwannoma patients with a mean follow-up 262 
of 47 months. Some of the patients that reported vertigo or unsteadiness were better 263 
at follow-up, and some were worse. No trends were reported.  264 
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We found that the function of the vestibular nerve as measured by caloric asymmetry 265 
did not seem to deteriorate over time as long as there was no tumor growth. This is in 266 
contrast with what is found when evaluating long-term hearing outcomes in untreated 267 
vestibular schwannoma patients. Several studies have investigated hearing outcome 268 
in treated and untreated vestibular schwannomas,26 and found that hearing 269 
deteriorates even if the tumor is not treated,16,27-28 but there is a lack of studies 270 
investigating changes in vestibular nerve function during conservative management 271 
and how it affects symptoms like vertigo and imbalance. 272 
In our study, postural unsteadiness was present in 17 % at baseline and 21 % at last 273 
follow-up. This is less than reported by others. Collins et al29 found that 49% of 274 
vestibular schwannoma patients had abnormal path lengths with eyes closed prior to 275 
surgery. Matthies and Samii tested balance with eyes closed and found abnormal 276 
results to be most common in patients with tumors compromising the brain stem, but 277 
almost equally (41%) in purely intrameatal tumors.4 278 
Gerosa30 found that 62% of patients had abnormal results on computerized static 279 
stabilometry before gamma knife radiosurgery. Indications for surgery might include 280 
larger tumors, growing tumors or more symptoms including dizziness and postural 281 
imbalance. In addition, preoperative patients may have increased postural sway due 282 
to nervousness. In a previous study we found that sway on the dynamic platform was 283 
associated with tumor size as well as subjective dizziness.14 In our study, patients 284 
had predominantly small tumors without tumor growth. Different prevalence of 285 
abnormal postural sway might also result from different choices of normative values. 286 
For static posturography, we used normative values from a previously published 287 
study using the same platform to measure the balance of healthy controls with a 288 
mean age of 52 years, which is slightly younger than in the present study. For 289 
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dynamic posturography, we used normative values integrated in the software 290 
supplied by the producer. 291 
Canal paresis was in this study found to be present in 51 % of cases at baseline and 292 
in 56 % at follow-up. Humphriss et al reported that 63 % of their cases had unilateral 293 
canal paresis,7 and in a group of patients selected for operation, 86 % had canal 294 
paresis defined as unilateral weakness >20%.31  295 
 296 
Strengths and Limitations 297 
To our knowledge, caloric function and posturography have not been measured in a 298 
long-term follow-up study of untreated vestibular schwannoma patients before, and 299 
longitudinal data on subjective vertigo are limited. The observation period in this 300 
study was relatively long with 10 years median radiologic follow-up. 301 
A limitation is the use of two different methods of posturography since they measure 302 
balance in different ways. However, for each individual patient, the same method was 303 
used at baseline and follow-up. This means that a change in measured postural sway 304 
would never be due to a change of method. Nevertheless, we did perform a separate 305 
analysis of the two platforms, and found that there was no change in postural sway 306 
during follow-up in either of them. Since the focus of this study was change during 307 
follow-up, we believe that the use of two different platforms was of no consequence 308 
to the conclusions. The VAS is not a validated method for quantifying dizziness, and 309 
the dizziness handicap inventory (DHI), might have been used to advantage. 310 
However, the distribution of VAS scores (Figure 3) in our study is quite similar to the 311 
distribution of DHI scores in the study from Humphriss32 and Lloyd3 indicating that the 312 
proportion of patients with moderate to severe symptoms might be comparable. 313 
 314 
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In this study only the caloric test was used as an indicator of vestibular nerve 315 
function, because this was the only method available to us at the time of inclusion.  316 
Adding other tests, like vestibular evoked myogenic potentials and video head 317 
impulse tests, could result in a higher detection of patients with impaired function of 318 
the vestibular nerve, particularly the inferior ramus. However, a change in function 319 
would normally have been detected since the same method was used throughout the 320 
follow-up period. Moreover, the caloric test has proven to be quite sensitive since in a 321 
previous study14 93% of patients with tumors larger than 20 mm were found to have a 322 
canal paresis greater than 25%. 323 
 324 
The most likely explanation for the findings in this study is that central compensation 325 
leads to a slight decrease in dizziness over time in patients with newly diagnosed 326 
vestibular schwannomas, and that this to some degree counteracts the effects of 327 
aging. Prerequisites for effective central compensation may be a non-growing tumor 328 
and stable peripheral vestibular function. 329 
 330 
The clinical significance of this finding is that patients may be reassured that the 331 
prognosis is relatively favorable with regards to vestibular symptoms during wait-and-332 
scan management of a non-growing tumor. Symptoms are likely to remain stable or 333 
even decrease slightly over time. Vestibular rehabilitation33 may be indicated to 334 
promote central compensation and improve physical function as well as quality of life 335 





This study found no significant change in the prevalence of moderate to severe 340 
dizziness, postural instability or canal paresis during long-term follow-up of 341 
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Table 1. 2 x 2 tables showing change in number of patients with dizziness*(N=100)  
unsteadiness (N=104) and canal paresis (N=72) from baseline to follow-up 
            
Dizziness* Yes f No f 
 
Unsteadiness Yes f No f 
 
Canal paresis Yes f No f 
 
               
Yes b 15 12  Yes b 13 5  Yes b 28 9 
 
               
No b 4 69  No b 9 77  No b 12 23  
                        
            



































Table 2.  Time course of dizziness at baseline and follow-up (mean 3.5 years) 
 in 98 patients with vestibular schwannoma *       











       
Attacks 15 15  17 17  
       
Periods  33 34  30 31  
       
Constant  7 7  9 9  
       
No dizziness 43 44  42 43  
              
       






















       
Table 3.  Dizziness character at baseline and follow-up (mean 3.4 years)  
in 91 patients with vestibular schwannoma* 
       
    Baseline  Follow-up  
Type of dizziness N %  N %  
       
Spinning 20 22  14 15  
       
Rocking 22 24  23 25  
       
Walking on pillows 5 6  8 9  
       
Other 1 1  5 6  
       
No dizziness 43 47  41 45  
       
       














Fig 1. Flow diagram showing treatment of 433 vestibular schwannoma patients 530 














Fig 2. Proportions with moderate to severe dizziness, unsteadiness and canal 544 























Fig 3. Distribution of VAS-score at baseline in 100 patients with untreated vestibular 560 
schwannomas. 561 
 562 
 563 
 564 
 565 
